You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 109 No. 7, July 1991 TABLE OF CONTENTS
  Archives
  •  Online Features
  CLINICOPATHOLOGIC REPORTS
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Immunohistochemistry of Terrien's and Mooren's Corneal Degeneration

Juan S. Lopez, MD; Francis W. Price, Jr, MD; Scott M. Whitcup, MD; Qian Li, MD; Marc de Smet, MD; Chi-Chao Chan, MD

Arch Ophthalmol. 1991;109(7):988-992.


Abstract

• Lamellar keratoplasty specimens from a patient with Terrien's marginal degeneration and a patient with Mooren's ulcer were compared using routine histopathologic and immunohistochemical staining with an avidin-biotin-peroxidase complex. Less than 25% of the resident cells in the Terrien's marginal degeneration specimen expressed major histocompatibility class II antigens compared with 75% to 100% of the resident cells in the Mooren's ulcer specimen. The ratio of CD4 cells (T-helper/inducer) to CD8 cells (T-suppressor/cytotoxic cells) in the Terrien's marginal degeneration specimen was almost 1:1 compared with 2.4:1 in the Mooren's ulcer specimen. In addition, less than 5% of the infiltrating cells from the Terrien's marginal degeneration specimen stained positive for CD22 (B cells), compared with 25% to 50% from the Mooren's ulcer specimen. These data may help explain why Terrien's marginal degeneration runs a more benign course than does Mooren's ulcer and provides a rationale for the use of immunosuppressive drugs to treat Mooren's ulcer.



Author Affiliations

From the Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, Md (Drs Lopez, Whitcup, Li, de Smet, and Chan), and the Cornea Research Foundation of America, Indianapolis, Ind (Dr Price).


Footnotes

Accepted for publication March 22, 1991.

Reprint requests to the Laboratory of Immunology, National Eye Institute, Bldg 10, Room ION 202, Bethesda, MD 20892 (Dr Lopez).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Mooren's ulcer in China: a study of clinical characteristics and treatment
Chen et al.
Br J Ophthalmol 2000;84:1244-1249.
ABSTRACT | FULL TEXT  

Immunopathology of uveitis
CHAN and LI
Br J Ophthalmol 1998;82:91-96.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1991 American Medical Association. All Rights Reserved.